C

Cara Therapeutics
D

CARA

0.42260
USD
0.01
(3.25%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
23,181,940
أصول ذات صلة
    A
    ACB
    0.18000
    (4.40%)
    4.27000 USD
    C
    CGC
    0.12000
    (4.44%)
    2.82000 USD
    C
    CRBP
    -0.370
    (-2.78%)
    12.960 USD
    C
    CRON
    0.09000
    (4.81%)
    1.96000 USD
    H
    HEXO
    -0.03000
    (-2.36%)
    1.23000 USD
    T
    TLRY
    0.09000
    (7.79%)
    1.24500 USD
    Z
    ZYNE
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار

العنوان: Cara Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.